10X Genomics, Inc. Stock Price, News & Analysis

10x Genomics (NASDAQ: TXG) launched the next generation of its Chromium Flex assay on October 29, 2025, introducing automation-compatible plate-based multiplexing to scale single cell studies.

The assay supports profiling up to 384 samples and 100 million cells per week in a 96-well plate format, claims improved sequencing efficiency and sensitivity from Flex chemistry, and aims to lower per-sample cost while reducing reagent waste. Early access customers at research institutes and pharma report faster throughput and compatibility with liquid-handling automation. New Flex is available globally and targets high-cell and high-sample applications such as CRISPR screens and FFPE translational studies.

10x Genomics (Nasdaq: TXG) and Anthropic announced on October 20, 2025 a collaboration to integrate 10x single cell and spatial analysis tools into Claude for Life Sciences using the Model Context Protocol (MCP).

The integration enables researchers to run common workflows—aligning reads, generating Feature Barcode matrices, clustering and other secondary analyses—via natural-language conversation rather than code, and connects Claude to 10x Cloud Analysis for scalable, large‑scale datasets.

10x Genomics (Nasdaq: TXG) will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 6, 2025. A public conference call and live webcast for analysts and investors will begin at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments and outlook. The news release with results will be posted on the company website before the call. Live audio will be available in the Investors section at https://investors.10xgenomics.com/ and the webcast will be archived for replay for at least 45 days.

10x Genomics (NASDAQ:TXG) has announced a significant research collaboration with CLISEQ Ltd. and the Weizmann Institute to launch the PERIBLOOD clinical trial, investigating single cell RNA sequencing as a non-invasive alternative to bone marrow aspiration for diagnosing blood disorders.

The three-year international study aims to enroll over 1,500 participants across multiple continents, utilizing 10x Genomics' Chromium GEM-X Single Cell technology. The trial builds on technology developed by Professors Liran Shlush and Amos Tanay, which successfully demonstrated MDS diagnosis from peripheral blood.

This groundbreaking research could potentially transform blood disorder diagnostics by replacing invasive bone marrow procedures with simple blood draws, marking one of the first international clinical programs evaluating single cell transcriptomics in real-world applications.

10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management team will engage in a fireside chat on September 10, at 11:30 a.m. Eastern Time.

Investors and interested parties can access the presentation through a live webcast on the company's investor relations website. The webcast recording will remain available for replay for at least 30 days following the event.

10x Genomics (Nasdaq: TXG) has launched Xenium Protein, an innovative addition to its Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell and tissue section in a single automated run. This breakthrough represents the first fully integrated spatial multiomic workflow for the Xenium platform.

The new product features ready-to-use protein subpanels that work alongside RNA panels, including dozens of proteins involved in cell growth, signaling, and immune response. The technology streamlines research workflows by eliminating the need for separate technologies or sample sections, particularly beneficial for studying cancer, immunology, and complex diseases.

Early adoption by companies like Sanofi demonstrates the platform's value in providing comprehensive tissue architecture analysis and cell-cell interaction insights without complex data co-registration requirements.

10x Genomics (NASDAQ: TXG) reported Q2 2025 financial results with total revenue of $172.9 million, including a $27.3 million patent litigation settlement. Excluding the settlement, revenue was $145.6 million, representing a 5% year-over-year decrease.

Key highlights include a $30 million acquisition of Scale Biosciences, improved gross margin of 72% (67% excluding license revenue), and net income of $34.5 million compared to a loss in the previous year. The company maintains a strong cash position of $447.3 million.

For Q3 2025, 10x Genomics projects revenue between $140-144 million, accounting for approximately $4 million in accelerated Chinese purchases due to potential tariff changes.

10x Genomics (Nasdaq: TXG) has announced a definitive agreement to acquire Scale Biosciences, a leader in innovative single cell analysis. The acquisition aims to enhance TXG's Chromium platform by integrating Scale's combinatorial indexing and quantum barcoding technologies.

The deal brings aboard Scale's scientific founders as advisors, including prominent researchers from Stanford University and University of Washington. The acquisition will support TXG's multi-year product roadmap focused on expanding single cell analysis capabilities, making it more powerful, affordable, and accessible to researchers globally.

10x Genomics will maintain support for existing Scale customers and continue key initiatives like the 100 Million Cell Challenge and the Billion Cells Project, while keeping core Scale products available in the market.

10x Genomics (Nasdaq: TXG) and A*STAR Genome Institute of Singapore have announced the TISHUMAP research collaboration to advance drug target discovery using spatial biology and AI. The study will analyze up to 2,500 FFPE clinical tissue samples from gastric, liver, and colorectal cancers using 10x Genomics' Xenium platform.

The collaboration leverages Xenium's unique capability to visualize gene activity within intact tissue samples at the cellular level, combined with AI to identify novel biomarkers and drug targets. The partnership includes development of custom gene panels and intelligent software pipelines to manage large-scale spatial biology data, aiming to accelerate the development of new diagnostics and personalized treatment approaches for cancer and inflammatory diseases.